Page last updated: 2024-09-04

moxifloxacin and nsc 663284

moxifloxacin has been researched along with nsc 663284 in 1 studies

Compound Research Comparison

Studies
(moxifloxacin)
Trials
(moxifloxacin)
Recent Studies (post-2010)
(moxifloxacin)
Studies
(nsc 663284)
Trials
(nsc 663284)
Recent Studies (post-2010) (nsc 663284)
3,1575521,69028020

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)nsc 663284 (IC50)
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus2.63
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 22.63
M-phase inducer phosphatase 1Homo sapiens (human)1.015
M-phase inducer phosphatase 2Homo sapiens (human)0.77
M-phase inducer phosphatase 3Homo sapiens (human)0.505
Dual specificity protein phosphatase 3Homo sapiens (human)4
N-lysine methyltransferase KMT5AHomo sapiens (human)0.21

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW1

Other Studies

1 other study(ies) available for moxifloxacin and nsc 663284

ArticleYear
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
    Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23

    Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors

2021